Partners Online Second Opinions

For those with complex medical questions or concerns, looking for answers or alternatives, or simply peace of mind – we are here to help.

Partners Online Second Opinions has provided thousands of patients and physicians remote access to the many specialists affiliated with Partners HealthCare, a Harvard Medical School-affiliated healthcare delivery system, based in Boston, Massachusetts.

The Partners HealthCare network includes top hospitals in the United States, including Massachusetts General Hospital, Brigham and Women’s Hospital, Dana Farber Cancer Institute, and Spaulding Rehabilitation Hospital. Many of our specialists are world-renowned experts in their field, and are available to review medical history and related materials, and provide you with a written consultation report.

When you are faced with decisions regarding a new diagnosis or treatment plan, having another expert opinion is the first step towards getting the care you need.

For 200 years, patients have been traveling to Boston to get some of the best care in the world. Now you can access this expertise from the comfort of your home.

Featured Specialist

Matthew Kulke, MD

Matthew Kulke, MD joined the DFCI staff in 1997 and is currently an Assistant Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute. He completed his undergraduate education at Princeton University, and received an M.D. from the University of California, San Francisco School of Medicine in 1992. He subsequently completed an internship and residency in internal medicine at Brigham and Women's Hospital, and a fellowship in medical oncology at Dana-Farber Cancer Institute. Dr. Kulke has led a multi-institutional trial of the novel angiogenesis inhibitor SU11248 in patients with neuroendocrine tumors, and has also served as study chair for a large, randomized trial of pancreatic cancer therapies performed by the Cancer and Leukemia group B. His recent efforts have focused on the evaluation of novel treatment agents and the identification novel treatment targets in neuroendocrine tumors.

Read More